214 related articles for article (PubMed ID: 9544528)
1. Gibbs sampling for long-term survival data with competing risks.
Chao EC
Biometrics; 1998 Mar; 54(1):350-66. PubMed ID: 9544528
[TBL] [Abstract][Full Text] [Related]
2. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
3. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
[TBL] [Abstract][Full Text] [Related]
4. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
[TBL] [Abstract][Full Text] [Related]
5. [Allogeneic peripheral blood stem cell transplantation for high-risk leukemia].
Huang X; Wang F; Guo N
Zhonghua Yi Xue Za Zhi; 2001 Nov; 81(22):1348-51. PubMed ID: 11930625
[TBL] [Abstract][Full Text] [Related]
6. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
7. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
[TBL] [Abstract][Full Text] [Related]
8. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
9. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
[TBL] [Abstract][Full Text] [Related]
10. Long-time survival after unrelated bone marrow transplantation in children and adolescents and targeted therapy with CD25 blockade to prevent GVHD.
Wawer A; Laws HJ; Dilloo D; Göbel U; Burdach S
Klin Padiatr; 2004; 216(3):169-75. PubMed ID: 15175962
[TBL] [Abstract][Full Text] [Related]
11. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.
Bacigalupo A; Lamparelli T; Barisione G; Bruzzi P; Guidi S; Alessandrino PE; di Bartolomeo P; Oneto R; Bruno B; Sacchi N; van Lint MT; Bosi A;
Biol Blood Marrow Transplant; 2006 May; 12(5):560-5. PubMed ID: 16635791
[TBL] [Abstract][Full Text] [Related]
12. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia.
Carlens S; Aschan J; Remberger M; Dilber M; Ringdén O
Bone Marrow Transplant; 1999 Sep; 24(6):629-35. PubMed ID: 10490728
[TBL] [Abstract][Full Text] [Related]
15. Graft-versus-leukaemia effect in children: chronic GVHD has a significant impact on relapse and survival.
Gustafsson Jernberg A; Remberger M; Ringdén O; Winiarski J
Bone Marrow Transplant; 2003 Feb; 31(3):175-81. PubMed ID: 12621478
[TBL] [Abstract][Full Text] [Related]
16. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
17. The graft-versus-leukaemia effect after allogeneic bone-marrow transplantation: assessment through competing risks approaches.
Katsahian S; Porcher R; Mary JY; Chevret S
Stat Med; 2004 Dec; 23(24):3851-63. PubMed ID: 15580602
[TBL] [Abstract][Full Text] [Related]
18. Mismatch of minor histocompatibility antigen contributes to a graft-versus-leukemia effect rather than to acute GVHD, resulting in long-term survival after HLA-identical stem cell transplantation in Japan.
Katagiri T; Shiobara S; Nakao S; Wakano M; Muranaka E; Kuba N; Furukawa T; Tsukada J; Takeda H; Aizawa Y; Harada M
Bone Marrow Transplant; 2006 Nov; 38(10):681-6. PubMed ID: 16980988
[TBL] [Abstract][Full Text] [Related]
19. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
[TBL] [Abstract][Full Text] [Related]
20. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
